| ［1］ |
Chiricozzi A, Caposiena D, Garofalo V, et al. A new therapeutic for the treatment of moderate⁃to⁃severe plaque psoriasis: apremilast［J］. Expert Rev Clin Immunol, 2016,12（3）:237⁃249. doi: 10.1586/1744666X.2016.1134319.
|
| ［2］ |
Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 inhibitors in immune⁃mediated diseases: mode of action, clinical applications, current and future perspectives［J］. Curr Med Chem, 2017,24（28）:3054⁃3067. doi: 10.2174/09298673246661 70530093902.
|
| ［3］ |
Page CP. Phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease［J］. Int Arch Allergy Immunol, 2014,165（3）:152⁃164. doi: 10.1159/000368800.
|
| ［4］ |
Jarnagin K, Chanda S, Coronado D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti⁃inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis［J］. J Drugs Dermatol, 2016,15（4）:390⁃396.
|
| ［5］ |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
|
| ［6］ |
Bissonnette R, Pavel AB, Diaz A, et al. Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial［J］. J Allergy Clin Immunol, 2019,144（5）:1274⁃1289. doi: 10.1016/j.jaci.2019.06.047.
|
| ［7］ |
Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 （PDE4） inhibitor for the topical treatment of atopic dermatitis （AD） in children and adults［J］. J Am Acad Dermatol, 2016,75（3）:494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
|
| ［8］ |
Eichenfield LF, Call RS, Forsha DW, et al. Long⁃term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis［J］. J Am Acad Dermatol, 2017,77（4）:641⁃649.e5. doi: 10.1016/j.jaad.2017.06.010.
|
| ［9］ |
Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild⁃to⁃moderate atopic dermatitis: a phaseⅣopen⁃label study （CrisADe CARE 1）［J］. Am J Clin Dermatol, 2020,21（2）:275⁃284. doi: 10.1007/s40257⁃020⁃00510⁃6.
|
| ［10］ |
Pao⁃Ling Lin C, Gordon S, Her MJ, et al. A retrospective study: application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor［J］. J Am Acad Dermatol, 2019,80（5）:1451⁃1453. doi: 10.1016/j.jaad.2018.10.054.
|
| ［11］ |
Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 （PDE4） inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phaseⅢ, randomized, controlled trial （Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis ［ESTEEM］ 1）［J］. J Am Acad Dermatol, 2015,73（1）:37⁃49. doi: 10.1016/j.jaad.2015.03.049.
|
| ［12］ |
Liu Y, Li W. Crisaborole ointment as treatment for genital psoriasis［J］. J Cosmet Dermatol, 2022,21（9）:4080⁃4081. doi: 10.1111/jocd.14706.
|
| ［13］ |
Lee EB, Lebwohl MG, Wu JJ. Treatment of psoriasis with crisaborole［J］. J Dermatolog Treat, 2019,30（2）:156⁃157. doi: 10.1080/09546634.2018.1480747.
|
| ［14］ |
Liu Y, Li W. Successful treatment with crisaborole for facial lesions refractory to adalimumab in a man with psoriasis: a case report［J］. Dermatol Ther, 2022,35（5）:e15424. doi: 10.1111/dth.15424.
|
| ［15］ |
Hashim PW, Chima M, Kim HJ, et al. Crisaborole 2% ointment for the treatment of intertriginous, anogenital, and facial psoriasis: a double⁃blind, randomized, vehicle⁃controlled trial［J］. J Am Acad Dermatol, 2020,82（2）:360⁃365. doi: 10.1016/j.jaad.2019.06.1288.
|
| ［16］ |
Robbins AB, Gor A, Bui MR. Topical crisaborole⁃a potential treatment for recalcitrant palmoplantar psoriasis［J］. JAMA Dermatol, 2018,154（9）:1096⁃1097. doi: 10.1001/jamadermatol. 2018.2397.
|
| ［17］ |
Majid I, Imran S, Batool S. Apremilast is effective in controlling the progression of adult vitiligo: a case series［J］. Dermatol Ther, 2019,32（4）:e12923. doi: 10.1111/dth.12923.
|
| ［18］ |
Tam I, Kahn JS, Rosmarin D. Repigmentation in a patient with vitiligo on crisaborole 2% ointment［J］. JAAD Case Rep, 2021,11:99⁃101. doi: 10.1016/j.jdcr.2021.03.028.
|
| ［19］ |
Sun X, Sheng A, Xu AE. Successful treatment of vitiligo with crisaborole ointment: a report of two cases［J］. Br J Dermatol, 2023,188（3）:436⁃437. doi: 10.1093/bjd/ljac092.
|
| ［20］ |
Li J, Feng Y, Liu C, et al. Presence of Malassezia hyphae is correlated with pathogenesis of seborrheic dermatitis［J］. Microbiol Spectr, 2022,10（1）:e0116921. doi: 10.1128/spectrum. 01169⁃21.
|
| ［21］ |
Liu D, Chow P, Strawn S, et al. Chronic nasolabial fold seborrheic dermatitis successfully controlled with crisaborole［J］. J Drugs Dermatol, 2018,17（5）:577⁃578.
|
| ［22］ |
Peña SM, Oak A, Smith AM, et al. Topical crisaborole is an efficacious steroid⁃sparing agent for treating mild⁃to⁃moderate seborrhoeic dermatitis［J］. J Eur Acad Dermatol Venereol, 2020,34（12）:e809⁃e812. doi: 10.1111/jdv.16673.
|
| ［23］ |
Ossorio⁃García L, Jiménez⁃Gallo D, Collantes⁃Rodríguez C, et al. Treatment of inflammatory linear verrucous epidermal nevus pruritus with thalidomide［J］. J Dtsch Dermatol Ges, 2018,16（9）:1141⁃1142. doi: 10.1111/ddg.13628.
|
| ［24］ |
Barney E, Prose NS, Ramirez M. Inflammatory linear verrucous epidermal nevus treated successfully with crisaborole ointment in a 5⁃year⁃old boy［J］. Pediatr Dermatol, 2019,36（3）:404⁃405. doi: 10.1111/pde.13793.
|
| ［25］ |
Altunay İK, Özkur E, Uğurer E, et al. More than a skin disease: stress, depression, anxiety levels, and serum neurotrophins in lichen simplex chronicus［J］. An Bras Dermatol, 2021,96（6）:700⁃705. doi: 10.1016/j.abd.2021.04.011.
|
| ［26］ |
Wei G, Rodriguez⁃Waitkus P, Soylu L. A rare case of lichen simplex chronicus in an adolescent female successfully managed with crisaborole［J］. Dermatol Ther, 2021,34（2）:e14752. doi: 10.1111/dth.14752.
|
| ［27］ |
Zeng X, Li L, Cui BN. Prurigo pigmentosa: a clinical and histopathological study of nine Chinese cases［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1794⁃1798. doi: 10.1111/jdv. 13659.
|
| ［28］ |
Mufti A, Mirali S, Abduelmula A, et al. Clinical manifestations and treatment outcomes in prurigo pigmentosa （Nagashima disease）: a systematic review of the literature［J］. JAAD Int, 2021,3:79⁃87. doi: 10.1016/j.jdin.2021.03.003.
|
| ［29］ |
Xu M, Wu N, Du Q, et al. Crisaborole: an emerging therapy for prurigo pigmentosa［J］. J Eur Acad Dermatol Venereol, 2022,36（6）:e441⁃e443. doi: 10.1111/jdv.17938.
|
| ［30］ |
Lu PH, Hui RC, Yang LC, et al. Prurigo pigmentosa: a clinicopathological study and analysis of associated factors［J］. Int J Dermatol, 2011,50（1）:36⁃43. doi: 10.1111/j.1365⁃4632. 2010.04625.x.
|
| ［31］ |
Zhang X, Zhao Y, Ye Y, et al. Lesional infiltration of mast cells, Langerhans cells, T cells and local cytokine profiles in alopecia areata［J］. Arch Dermatol Res, 2015,307（4）:319⁃331. doi: 10. 1007/s00403⁃015⁃1539⁃1.
|
| ［32］ |
Suárez⁃Fariñas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL⁃23 cytokine activation without parallel TH17/TH22 skewing［J］. J Allergy Clin Immunol, 2015,136（5）:1277⁃1287. doi: 10.1016/j.jaci.2015.06.032.
|
| ［33］ |
Avitabile S, Sordi D, Garcovich S, et al. Effective squaric acid dibutylester immunotherapy is associated with a reduction of skin infiltrating T⁃helper （Th）1 and Th17 cells in alopecia areata patients［J］. J Dermatol, 2015,42（1）:98⁃99. doi: 10.1111/1346⁃8138.12740.
|
| ［34］ |
Taneja N, Gupta S. Apremilast is efficacious in refractory alopecia areata［J］. J Dermatolog Treat, 2020,31（7）:727⁃729. doi: 10.1080/09546634.2019.1616046.
|
| ［35］ |
张帆, 糜自豪, 孙勇虎. 外用磷酸二酯酶4抑制剂软膏治疗斑秃一例附文献复习［J］. 中国麻风皮肤病杂志, 2022,38（4）:217⁃219. doi: 10.12144 /zgmfskin202204217
|
| ［36］ |
Serrão LM, Sarmenghi KDA, Pinto BCBP, et al. Thalidomide in plasma cell balanitis refractory to conventional topical treatment［J］. An Bras Dermatol, 2018,93（6）:881⁃883. doi:10.1590/abd1806⁃4841.20187462.
|
| ［37］ |
Piaserico S, Orlando G, Linder MD, et al. A case⁃control study of risk factors associated with Zoon balanitis in men［J］. J Eur Acad Dermatol Venereol, 2019,33（8）:1591⁃1594. doi: 10.1111/jdv.15594.
|
| ［38］ |
Niu X, Yang X, Wang F, et al. A novel and effective therapy for Zoon balanitis: topical crisaborole 2% ointment［J］. J Eur Acad Dermatol Venereol, 2023,37（2）:e212⁃e214. doi: 10.1111/jdv. 18494.
|
| ［39］ |
Solimani F, Forchhammer S, Schloegl A, et al. Lichen planus ⁃ a clinical guide［J］. J Dtsch Dermatol Ges, 2021,19（6）:864⁃882. doi: 10.1111/ddg.14565.
|
| ［40］ |
Lu H, He R, Yang S, et al. Successful treatment of pediatric lichen planus with topical Crisaborole［J］. Dermatol Ther, 2022,35（12）:e15893. doi: 10.1111/dth.15893.
|
